At Mount Sinai's Icahn School of Medicine in New York City, researchers have made a counterintuitive discovery: the same focused radiation beams used to kill cancer cells may also hold the key to making immune cell therapy work better against solid tumors like lung cancer and melanoma. Their findings, published in Nature Cancer, reveal that irradiation can transform the immune landscape inside a tumor, allowing laboratory-engineered CAR-T cells to survive longer and multiply more effectively—ultimately controlling advanced cancers that CAR-T therapy alone cannot defeat.
CAR-T cell therapy has revolutionized treatment for blood cancers. The approach is elegantly simple: remove a patient's own T cells, reprogram them in the laboratory to recognize and attack cancer, and return them to the bloodstream. Yet this same strategy has repeatedly stumbled against solid tumors, where patients typically face bulky, treatment-resistant disease. The central problem is persistence: CAR-T cells reach the tumor but their numbers dwindle before they can finish the job, allowing cancer to regrow.
The Mount Sinai team, led by corresponding author Dr. Jalal Ahmed, discovered an unexpected mechanism that could change this trajectory. When researchers delivered focused irradiation to tumors in mouse models of advanced lung cancer and melanoma, something remarkable happened. The radiation activated dendritic cells—the immune system's most powerful antigen-presenting cells—within the tumor itself. These dendritic cells began capturing intact tumor surface proteins and displaying them on their own membranes in a process called "antigen dressing." Crucially, these antigen-dressed dendritic cells then engaged directly with the engineered receptor on CAR-T cells, keeping them alive and multiplying steadily throughout the tumor over several weeks.
"This was completely unexpected," Dr. Ahmed said in a statement about the discovery. "Dendritic cells normally engage T cells through an entirely different mechanism." The result was durable control of advanced lung tumors that CAR-T cells alone had been unable to eliminate—a meaningful shift in what had seemed like a fundamental limitation of the therapy.
Beyond efficacy lies an equally pressing concern: safety. One of the most serious barriers to solid tumor CAR-T cell therapy is the risk of on-target toxicity, where CAR-T cells become overactive in healthy tissues that happen to express the same protein being targeted. This safety problem has derailed clinical trials. The Mount Sinai research revealed that focused irradiation confines the CAR-T cell response largely to the irradiated tumor itself. CAR-T cells expanded within the tumor but remained largely inactive in nearby healthy tissues, even when those tissues expressed the targeted protein.
"What is striking is that irradiation does not just amplify the immune response—it tells the immune system where to act," said study co-author Dr. Miriam Merad, Robin Chemers Neustein Professor of Immunology and Chair of the Icahn School of Medicine's Immunology and Immunotherapy department. This precise localization could allow clinicians to treat advanced tumors using lower, safer doses of CAR-T cells.
The path to patients may move faster than typical for experimental therapies. The irradiation approach used in the study is already available in cancer care centers worldwide, meaning clinical trials could begin without requiring new equipment or drugs. For patients with metastatic solid tumors—who currently face limited options—this combination strategy represents genuine hope grounded in rigorous science.